Current Report Filing (8-k)
June 24 2019 - 6:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
June 24, 2019 (June 21, 2019)
Date of Report (Date of earliest event reported)
ELITE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its
charter)
Nevada
|
|
001-15697
|
|
22-3542636
|
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number
|
|
Identification No.)
|
165 Ludlow Avenue, Northvale, New Jersey
07647
(Address of principal executive offices)
(201) 750-2646
(Registrant’s telephone number, including
area code)
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth
company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant
to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
|
|
|
|
|
Item
2.02. Results of Operations and Financial Condition.
On June 21, 2019, Elite Pharmaceuticals,
Inc. ("Elite" or the “Company") filed its annual report on Form 10-K for the year ended March 31, 2019 and,
thereafter, issued a press release announcing its financial results for that quarter. A copy of the press release is furnished
as Exhibit 99.1 hereto and is incorporated herein by reference.
As noted in the press release, the Company will host a conference
call at 11:30 AM Eastern Daylight Time (EDT) on Monday, June 24th, 2019, to provide a general business update. Elite will respond
to various stockholder questions submitted prior to the call.
Conference Call Information
Date:
|
Monday, June 24, 2019
|
Time:
|
11:30 AM EDT
|
Dial-in numbers:
|
1-800-346-7359 (domestic)
|
|
1-973-528-0008 (international)
|
Conference number:
|
98840
|
Questions:
|
dianne@elitepharma.com by 8:00 PM EDT on
Saturday, June 22, 2019
|
Audio Replay:
|
http://elite.irpass.com/events_presentations
|
Item 7.01 Regulation FD
Disclosure.
The information disclosed
in Item 2.02 above is incorporated into this Item 7.01. The information included in this Current Report on Form 8-K (including
the exhibit hereto) is being furnished under Item 2.02, "Results of Operations and Financial Condition," Item 7.01,
"Regulation FD Disclosure" and Item 9.01 "Financial Statements and Exhibits" of Form 8-K. As such, the information
(including the exhibit) herein shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it
be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any
general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing.
This Current Report (including the exhibit hereto) will not be deemed an admission as to the materiality of any information required
to be disclosed solely to satisfy the requirements of Regulation FD.
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ELITE PHARMACEUTICALS, INC.
|
|
|
Dated: June 24, 2019
|
By:
|
/s/ Nasrat Hakim
|
|
|
Nasrat Hakim, President and CEO
|
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Apr 2023 to Apr 2024